1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Brachytherapy Seeds Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Brachytherapy Seeds Market Analysis and Forecast, 2017-2031
4.4.1. Market Revenue Projections (US$ Mn)
4.4.2. Market Volume/Unit Shipments Projections
4.5. Porter’s Five Forces Analysis
5. Key Insights
5.1. Key Mergers & Acquisitions
5.2. Key Radioactive Seed Type/Brand Analysis
5.3. Patent Analysis
5.4. Top 3 Players Operating in the Market Space
5.5. COVID-19 Pandemic Impact on Industry (value chain and short/mid/long term impact)
6. Global Brachytherapy Seeds Market Analysis and Forecast, by Radioactive Seed Type
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Radioactive Seed Type, 2017-2031
6.3.1. Iodine-125
6.3.2. Palladium-103
6.3.3. Cesium-131
6.3.4. Others
6.4. Market Attractiveness Analysis, by Radioactive Seed Type
7. Global Brachytherapy Seeds Market Analysis and Forecast, by Technique
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Technique, 2017-2031
7.3.1. HRD Brachytherapy
7.3.2. LDR Brachytherapy
7.4. Market Attractiveness Analysis, by Technique
8. Global Brachytherapy Seeds Market Analysis and Forecast, by Application
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Application, 2017-2031
8.3.1. Gynecological Cancer
8.3.2. Prostate Cancer
8.3.3. Breast Cancer
8.3.4. Brain Cancer
8.3.5. Others
8.4. Market Attractiveness Analysis, by Application
9. Global Brachytherapy Seeds Market Analysis and Forecast, by End-user
9.1. Introduction & Definition
9.2. Key Findings/Developments
9.3. Market Value Forecast, by End-user, 2017-2031
9.3.1. Hospitals
9.3.2. Cancer Institutes
9.3.3. Others
9.4. Market Attractiveness Analysis, by End-user
10. Global Brachytherapy Seeds Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region, 2017-2031
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness Analysis, By Region
11. North America Brachytherapy Seeds Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Radioactive Seed Type, 2017-2031
11.2.1. Iodine-125
11.2.2. Palladium-103
11.2.3. Cesium-131
11.2.4. Others
11.3. Market Value Forecast, by Technique, 2017-2031
11.3.1. HRD Brachytherapy
11.3.2. LDR Brachytherapy
11.4. Market Value Forecast, by Application, 2017-2031
11.4.1. Gynecological Cancer
11.4.2. Prostate Cancer
11.4.3. Breast Cancer
11.4.4. Brain Cancer
11.4.5. Others
11.5. Market Value Forecast, by End-user, 2017-2031
11.5.1. Hospitals
11.5.2. Cancer Institutes
11.5.3. Others
11.6. Market Value Forecast, by Country, 2017-2031
11.6.1. U.S.
11.6.2. Canada
11.7. Market Attractiveness Analysis
11.7.1. By Radioactive Seed Type
11.7.2. By Technique
11.7.3. By Application
11.7.4. By End-user
11.7.5. By Country
12. Europe Brachytherapy Seeds Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Radioactive Seed Type, 2017-2031
12.2.1. Iodine-125
12.2.2. Palladium-103
12.2.3. Cesium-131
12.2.4. Others
12.3. Market Value Forecast, by Technique, 2017-2031
12.3.1. HRD Brachytherapy
12.3.2. LDR Brachytherapy
12.4. Market Value Forecast, by Application, 2017-2031
12.4.1. Gynecological Cancer
12.4.2. Prostate Cancer
12.4.3. Breast Cancer
12.4.4. Brain Cancer
12.4.5. Others
12.5. Market Value Forecast, by End-user, 2017-2031
12.5.1. Hospitals
12.5.2. Cancer Institutes
12.5.3. Others
12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Italy
12.6.5. Spain
12.6.6. Rest of Europe
12.7. Market Attractiveness Analysis
12.7.1. By Radioactive Seed Type
12.7.2. By Technique
12.7.3. By Application
12.7.4. By End-user
12.7.5. By Country/Sub-region
13. Asia Pacific Brachytherapy Seeds Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Radioactive Seed Type, 2017-2031
13.2.1. Iodine-125
13.2.2. Palladium-103
13.2.3. Cesium-131
13.2.4. Others
13.3. Market Value Forecast, by Technique, 2017-2031
13.3.1. HRD Brachytherapy
13.3.2. LDR Brachytherapy
13.4. Market Value Forecast, by Application, 2017-2031
13.4.1. Gynecological Cancer
13.4.2. Prostate Cancer
13.4.3. Breast Cancer
13.4.4. Brain Cancer
13.4.5. Others
13.5. Market Value Forecast, by End-user, 2017-2031
13.5.1. Hospitals
13.5.2. Cancer Institutes
13.5.3. Others
13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
13.6.1. China
13.6.2. Japan
13.6.3. India
13.6.4. Australia & New Zealand
13.6.5. Rest of Asia Pacific
13.7. Market Attractiveness Analysis
13.7.1. By Radioactive Seed Type
13.7.2. By Technique
13.7.3. By Application
13.7.4. By End-user
13.7.5. By Country/Sub-region
14. Latin America Brachytherapy Seeds Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Radioactive Seed Type, 2017-2031
14.2.1. Iodine-125
14.2.2. Palladium-103
14.2.3. Cesium-131
14.2.4. Others
14.3. Market Value Forecast, by Technique, 2017-2031
14.3.1. HRD Brachytherapy
14.3.2. LDR Brachytherapy
14.4. Market Value Forecast, by Application, 2017-2031
14.4.1. Gynecological Cancer
14.4.2. Prostate Cancer
14.4.3. Breast Cancer
14.4.4. Brain Cancer
14.4.5. Others
14.5. Market Value Forecast, by End-user, 2017-2031
14.5.1. Hospitals
14.5.2. Cancer Institutes
14.5.3. Others
14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of Latin America
14.7. Market Attractiveness Analysis
14.7.1. By Radioactive Seed Type
14.7.2. By Technique
14.7.3. By Application
14.7.4. By End-user
14.7.5. By Country/Sub-region
15. Middle East & Africa Brachytherapy Seeds Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Radioactive Seed Type, 2017-2031
15.2.1. Iodine-125
15.2.2. Palladium-103
15.2.3. Cesium-131
15.2.4. Others
15.3. Market Value Forecast, by Technique, 2017-2031
15.3.1. HRD Brachytherapy
15.3.2. LDR Brachytherapy
15.4. Market Value Forecast, by Application, 2017-2031
15.4.1. Gynecological Cancer
15.4.2. Prostate Cancer
15.4.3. Breast Cancer
15.4.4. Brain Cancer
15.4.5. Others
15.5. Market Value Forecast, by End-user, 2017-2031
15.5.1. Hospitals
15.5.2. Cancer Institutes
15.5.3. Others
15.6. Market Value Forecast, by Country/Sub-region, 2017-2031
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Rest of Middle East & Africa
15.7. Market Attractiveness Analysis
15.7.1. By Radioactive Seed Type
15.7.2. By Technique
15.7.3. By Application
15.7.4. By End-user
15.7.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player – Competition Matrix (by tier and size of companies)
16.2. Market Share Analysis, by Company, 2021
16.3. Company Profiles
16.3.1. Argon Medical
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Product Portfolio
16.3.1.3. Financial Overview
16.3.1.4. SWOT Analysis
16.3.1.5. Strategic Overview
16.3.2. Carl Zeiss AG
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Product Portfolio
16.3.2.3. Financial Overview
16.3.2.4. SWOT Analysis
16.3.2.5. Strategic Overview
16.3.3. Eckert & Ziegler BEBIG
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Product Portfolio
16.3.3.3. Financial Overview
16.3.3.4. SWOT Analysis
16.3.3.5. Strategic Overview
16.3.4. Elektra AB
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Product Portfolio
16.3.4.3. Financial Overview
16.3.4.4. SWOT Analysis
16.3.4.5. Strategic Overview
16.3.5. Icad, Inc.
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Product Portfolio
16.3.5.3. Financial Overview
16.3.5.4. SWOT Analysis
16.3.5.5. Strategic Overview
16.3.6. Isoaid
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Product Portfolio
16.3.6.3. Financial Overview
16.3.6.4. SWOT Analysis
16.3.6.5. Strategic Overview
16.3.7. Isoray Medical, Inc.
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Product Portfolio
16.3.7.3. Financial Overview
16.3.7.4. SWOT Analysis
16.3.7.5. Strategic Overview
16.3.8. Merit Medical Systems, Inc.
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Product Portfolio
16.3.8.3. Financial Overview
16.3.8.4. SWOT Analysis
16.3.8.5. Strategic Overview
16.3.9. Siemens AG
16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.9.2. Product Portfolio
16.3.9.3. Financial Overview
16.3.9.4. SWOT Analysis
16.3.9.5. Strategic Overview
16.3.10. Theragenics Corporation
16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.10.2. Product Portfolio
16.3.10.3. Financial Overview
16.3.10.4. SWOT Analysis
16.3.10.5. Strategic Overview
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer